Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

FDA grants second orphan drug designation for ImmTher

July 20, 1998

Medarex begins clinical trials of Bispecific antibody for cancer

July 20, 1998

Phase II trial of Avicine in prostate cancer announced

July 17, 1998

AltaRex initiates second phase II trial of OvaRex

July 16, 1998

Theragyn phase III testing will begin in U.K.

July 13, 1998

Regressin holds promise for a wide range of cancers, new data indicates

July 13, 1998

IL-4 fusion toxin shows potent antitumor activity in murine model of KS

July 10, 1998

NeoPharm scales up IL13-PE38QQR manufacturing

July 10, 1998

GOG will evaluate Avax Technologies' ovarian cancer vaccine in phase I/II study

July 6, 1998

Herceptin licensed to Roche for most markets

July 6, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...